Sector: Health Care
Director information for LIQUIDIA CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Arthur Kirsch | Chairperson of our Audit Committee | 74 | ["consultant","managing director and senior advisor for GCA Global, LLC","executive vice president, head of research at Vector Securities, LLC","president of Natwest Securities Limited","executive vice president, head of equity division at Drexel Burnham Lambert, Inc.","Bachelor of Science from the University of Rhode Island","Master of Business Administration from Baruch College","business and financial expertise","experience serving on the boards of directors of several public pharmaceutical and life sciences companies"] | ["Audit Committee","Compensation Committee","Litigation Committee"] | 2026 |
| Damian deGoa | Director | 47 | ["Chief Operating Officer at Ottawa Avenue Private Capital","Chief Executive Officer from December 2020 to January 2022","Managing Director of PBM Capital Group, LLC","Chief Executive Officer of Breas Medical Group","various roles at Perrigo Company including Head of International Business Development"] | ["Audit Committee"] | 2026 |
| David Johnson | Director | 43 | ["Managing Partner and co-Founder of Caligan","experience as Managing Director at The Carlyle Group","experience at Morgan Stanley","A.B. in Applied Mathematics, cum laude from Harvard College","S.M. in Applied Mathematics from Harvard College"] | ["Audit Committee","Research and Development Committee"] | 2026 |
| Joanna Horobin, M.B., C.H.B. | Director | 71 | ["Chairperson of Compensation Committee","Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals","Chief Medical Officer of Verastem","President of Syndax Pharmaceuticals","Experience in global pharmaceutical corporations"] | ["Compensation Committee","Research and Development Committee","Litigation Committee"] | 2026 |
| Katie Rielly-Gauvin | Director | 62 | ["Vice President of Global Commercial Development of AbbVie Inc.","Oversaw and led strategic direction and expansion in Immunology, Oncology, Neuroscience and Specialty Therapeutic areas","Worked in various roles in commercial, medical affairs, and research capacities at Johnson & Johnson"] | ["Nominating and Corporate Governance Committee","Compensation Committee","Research and Development Committee","Litigation Committee"] | 2026 |
| Paul B. Manning | Chairman and Chief Executive Officer | 70 | ["Chairman and Chief Executive Officer of PBM Capital Group","founder of PBM Products","director of Verrica Pharmaceuticals, Inc.","director of Candel Therapeutics, Inc.","managerial and operational experience in the healthcare industry","investor in healthcare related companies","B.S. in microbiology from the University of Massachusetts"] | [] | 2026 |
| Ramandeep Singh | Director | 55 | ["Bachelor’s degree in Mechanical Engineering","Master’s degree in International Management","Master’s degree in Business Administration","experience as Chief Executive Officer of Juniper Biologics","experience as Chief Executive Officer of Mundipharma Pte Limited"] | ["Audit Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Roger A. Jeffs, Ph.D. | Chief Executive Officer and Director | 64 | ["Co-Founder and Vice Chairman of Kriya Therapeutics","Experience at United Therapeutics Corporation","Director of Research, Development, and Medical at United Therapeutics"] | ["Compensation Committee","Research and Development Committee","Litigation Committee"] | 2026 |
| Stephen Bloch, M.D. | Chairperson | 63 | ["financial expertise","experience as a venture capitalist","experience serving on the board of directors for several public and private pharmaceutical and life sciences companies"] | ["Audit Committee","Nominating and Corporate Governance Committee","Compensation Committee"] | 2026 |
